South Korea’s securities regulators said Samsung BioLogics intentionally violated accounting rules and they suspended trading of its stock. Merck & Co. will provide $1.2 billion worth of Gardasil vaccines to China in 2020. Chinese authorities proposed new draft regulation to crack down on future illegal vaccine practices. And more. 1. Samsung Czytaj więcej…
AstraZeneca has spent the last 16 months trying to keep investors’ hopes alive that a key immuno-oncology trial in the all-important previously untreated lung cancer field could still turn out positive after an initial flop. But it didn’t. On Friday, the British drugmaker said that both Imfinzi on its own Czytaj więcej…
Love. Ahhhhh… they say it makes the world go ‘round. But does it? Does it always make us feel all warm and fuzzy inside? Or does it sometimes cause us problems in our relationships? Well, the answer is both. We have all had our share of relationship problems – especially Czytaj więcej…
In new research studying how genetic factors determine taste, scientists now believe they know why some humans prefer coffee while others opt for tea. A paper published this week in the journal Nature Scientific Reports found that people who are genetically predisposed to like more bitter tastes typically choose coffee Czytaj więcej…
Rachel Agutter’s parents were told she would only live till 12 – now 40, she talks to PharmaTimes about living with a disease where her luck could run out at any moment How were you diagnosed with cystic fibrosis, and what were your symptoms? I was diagnosed at 6 months Czytaj więcej…
James Huang & Stephen Huang on the groundbreaking technologies that could change precision medicine in the near future For an industry known for its glacial pace and caution, 2018 has seen remarkable breakthroughs in a wide range of emerging technologies. From 3-D printing and genome sequencing to nanotechnology and artificial Czytaj więcej…
…But this year its impact, and the potential for change, was felt across the pharma industry 2018 has seen a surge in interest in artificial intelligence (AI) and its use in the pharmaceutical industry. When considering the reasons for this, the answer is not that AI is new. ‘AI’ is Czytaj więcej…
The biggest cases of the past year March 2018 – UK Court of Appeal Judgment in Regeneron v Kymab This is an important judgement on sufficiency. Regeneron’s patents relate to methods of producing human antibodies using transgenic mice. The mice are produced by “in situ replacement” of mouse variable regions Czytaj więcej…
The NHS has been taking an increasingly joined-up approach to care during 2018, significantly altering how it works with pharma In 2018, four more Sustainability and Transformation Partnerships (STPs) were given the green light to form Integrated Care Systems (ICSs) and there was a renewed commitment to this joined-up style Czytaj więcej…
The true impact of biosimilars is starting to be felt across the industry Biologics and biosimilars are nothing new. Following the success of biologics, the first biosimilar was approved in Europe, which has a more mature biosimilar market than the US, over twelve years ago. However, it is only relatively Czytaj więcej…